The drug delivery technology of Eyesiu is based on a nanoparticle composed of a lipophilic therapeutic and a PEGylated lipid mix. The solvent-free lipid nanoparticle captures the therapeutic and avoids its precipitation in biological fluids. This enables the absorption of the therapeutic by cells and significantly increases its action and therefore its effect. 



The company has developed four drug products in order to target a wide range of indications:

  • YCU-82:

The YCU-82 product is designed for ophthalmology indications. This clear and solvent-free product is based on Aptar Pharma’s eye drop dispenser and it will reach the back of the eye because of the stable and inert PEGylated lipid nanoparticles. YCU-82 has the potential to target several inflammatory eye diseases.

  • YCU-jet:

The YCU-jet product is applied by means of Aptar Pharma’s spray and it can target different dermatology indications. This solvent-free liquid product is ideal for parts of the body where applying a cream is inconvenient and/or irritated parts of the body where friction or stinging solvents are not preferred.

  • YCU-nasal:

The YCU-nasal product is designed for neurological indications. This solvent-free and concentrated product is based on Aptar Pharma’s nasal spray pump and it will reach central nervous system because of the stable and inert PEGylated lipid nanoparticles. YCU-nasal can be conveniently applicable to treat chronic neurodegenerative diseases.

  • YCU- inhale:

The YCU-inhale product is administrated by means of Aptar Pharma´s metered dose inhaler and it can target pulmonology indications. Through the inhaler, the lipid nanoparticles carrying the therapeutic can be delivered directly into the smaller airways of the lungs.